Search results
Project Manager. Dr. Stephen Lam is Professor of Medicine at the University of British Columbia. He is a respirologist at BC Cancer, a Distinguished Scientist and Leon Judah Blackmore Chair in Lung Cancer Research at the BC Cancer Research Center. He is an endowed director of the MDS-Rix Early Lung Cancer Detection and Translational Research ...
- Resources
The safety office is comprised of a Biosafety Officer and a...
- About Us
Researching the optical, radiobiological and genetic...
- Stephen Lam Lab
Dr. Stephen Lam is the Principal Investigator of the...
- Resources
Dr. Lam’s research focuses on early detection and chemoprevention of lung cancer. His long-term goal is to translate scientific research in lung cancer screening to implementation at the population level and to improve lung cancer outcome.
People also ask
Who is Stephen Lam?
What is Dr Lam's Research focusing on?
Who is Professor Lam?
Who is David Lam MD?
Apr 18, 2016 · Dr. Stephen Lam is a professor of medicine at the University of British Columbia (UBC). He chairs the Provincial Lung Tumor Group and directs the MDS-Rix Early Lung Cancer Detection and Translational Research Program at BC Cancer. His research interest is in early detection, chemoprevention and endoscopic therapy of lung cancer.
Sep 25, 2017 · September 25, 2017. Dr. Stephen Lam, Professor in the UBC Department of Medicine and distinguished scientist in the Department of Integrative Oncology at the BC Cancer Research Centre. Dr. Stephen Lam is an award-winning scientist whose research on the early detection of lung cancer is saving lives. He’s currently conducting international ...
He is an interventional pulmonologist and medical director of the BC Lung Screening Program at BC Cancer. He is an expert adviser of the Canadian Partnership Against Cancer and chairs the partnership’s Pan-Canadian Lung Cancer Screening Network.
Research Interests. Evaluation of chemopreventive agents including the use of herbal compounds to prevent lung cancer. Development and validation of surrogate end-point biomarkers for Phase II chemoprevention clinical trials of new chemopreventive agents.
